Johnson & Johnson

146.97+2.08+1.44%Vol 6.07M1Y Perf 7.39%
May 28th, 2020 16:00 DELAYED
BID146.00 ASK147.72
Open146.02 Previous Close144.89
Pre-Market146.53 After-Market146.98
 -0.44 -0.30%  0.01 0.01%
Target Price
165.31 
Analyst Rating
Moderate Buy 1.56
Potential %
12.48 
Finscreener Ranking
★★     47.17
Insiders Trans % 3/6/12 mo.
100/-43/-25 
Value Ranking
★★     48.98
Insiders Value % 3/6/12 mo.
100/-94/-90 
Growth Ranking
★★★★     59.55
Insiders Shares Cnt. % 3/6/12 mo.
100/-93/-90 
Income Ranking
★★+     45.95
Market Cap387.21B 
Earnings Rating
Sell
Price Range Ratio 52W %
79.03 
Earnings Date
21st Jul 2020

Today's Price Range

145.81148.11

52W Range

109.16157.00

5 Year PE Ratio Range

14.30310.40

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
1.80%
1 Month
-2.18%
3 Months
9.29%
6 Months
6.90%
1 Year
7.39%
3 Years
15.80%
5 Years
48.98%
10 Years
200.77%

TickerPriceChg.Chg.%
JNJ146.972.08001.44
AAPL318.250.14000.04
GOOG1 416.73-1.1100-0.08
MSFT181.40-0.4100-0.23
XOM45.04-1.2000-2.60
WFC27.22-0.7300-2.61
FB225.46-3.6800-1.61
GE6.78-0.5100-7.00
JPM99.86-1.5100-1.49
Financial StrengthValueIndustryS&P 500US Markets
1.00
1.30
0.29
0.45
81.60
Leverage Ratio 2.60
ProfitabilityValueIndustryS&P 500US Markets
66.20
23.80
32.20
24.20
20.75
RevenueValueIndustryS&P 500US Markets
82.73B
31.38
3.99
3.17
DividendsValueIndustryS&P 500US Markets
2.80
4.04
5.22
5.86
Payout ratio66.00
Earnings HistoryEstimateReportedSurprise %
Q01 20202.032.3013.30
Q04 20191.861.881.08
Q03 20192.002.126.00
Q02 20192.422.586.61
Q01 20192.032.103.45
Q04 20181.951.971.03
Q03 20182.032.050.99
Q02 20182.062.101.94
Earnings Per EndEstimateRevision %Trend
6/2020 QR1.45-35.56Negative
9/2020 QR2.03-17.48Negative
12/2020 FY7.68-14.95Negative
12/2021 FY9.18-5.36Negative
Next Report Date21st Jul 2020
Estimated EPS Next Report1.45
Estimates Count7
EPS Growth Next 5 Years %6.00
Volume Overview
Volume6.07M
Shares Outstanding2.63B
Trades Count62.51K
Dollar Volume1.18B
Avg. Volume9.94M
Avg. Weekly Volume6.39M
Avg. Monthly Volume7.03M
Avg. Quarterly Volume11.55M

Johnson & Johnson (NYSE: JNJ) stock closed at 146.97 per share at the end of the most recent trading day (a 1.44% change compared to the prior day closing price) with a volume of 6.19M shares and market capitalization of 387.21B. Is a component of S&P 500, Dow Jones 30, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 135100 people. Johnson & Johnson CEO is Alex Gorsky.

The one-year performance of Johnson & Johnson stock is 7.39%, while year-to-date (YTD) performance is 0.75%. JNJ stock has a five-year performance of 48.98%. Its 52-week range is between 109.16 and 157, which gives JNJ stock a 52-week price range ratio of 79.03%

Johnson & Johnson currently has a PE ratio of 22.50, a price-to-book (PB) ratio of 6.21, a price-to-sale (PS) ratio of 4.60, a price to cashflow ratio of 16.60, a PEG ratio of 2.32, a ROA of 11.25%, a ROC of 19.29% and a ROE of 28.55%. The company’s profit margin is 20.75%, its EBITDA margin is 32.20%, and its revenue ttm is $82.73 Billion , which makes it $31.38 revenue per share.

Of the last four earnings reports from Johnson & Johnson, there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $1.45 for the next earnings report. Johnson & Johnson’s next earnings report date is 21st Jul 2020.

The consensus rating of Wall Street analysts for Johnson & Johnson is Moderate Buy (1.56), with a target price of $165.31, which is +12.48% compared to the current price. The earnings rating for Johnson & Johnson stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Johnson & Johnson has a dividend yield of 2.80% with a dividend per share of $4.04 and a payout ratio of 66.00%.

Johnson & Johnson has a Neutral technical analysis rating based on Technical Indicators (ADX : 12.41, ATR14 : 3.23, CCI20 : -48.50, Chaikin Money Flow : -0.10, MACD : 0.10, Money Flow Index : 41.14, ROC : -0.12, RSI : 50.39, STOCH (14,3) : 37.32, STOCH RSI : 0.67, UO : 38.82, Williams %R : -62.68), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Johnson & Johnson in the last 12-months were: Alex Gorsky (Option Excercise at a value of $0), Ashley McEvoy (Option Excercise at a value of $0), Hubert Joly (Buy at a value of $706 399), Jennifer L. Taubert (Option Excercise at a value of $0), Joaquin Duato (Option Excercise at a value of $0), Joseph J. Wolk (Option Excercise at a value of $0), Kathryn E. Wengel (Option Excercise at a value of $126 305), Kathryn E. Wengel (Sold 2 017 shares of value $284 538 ), Kathy Wengel (Option Excercise at a value of $126 305), Kathy Wengel (Sold 2 017 shares of value $284 538 ), Marillyn A. Hewson (Buy at a value of $419 040), Michael E. Sneed (Option Excercise at a value of $3 639 975), Michael E. Sneed (Sold 58 128 shares of value $8 683 568 ), Michael H. Ullmann (Option Excercise at a value of $0), Michael Sneed (Option Excercise at a value of $3 639 975), Michael Sneed (Sold 58 128 shares of value $8 683 568 ), Paulus Stoffels (Option Excercise at a value of $0), Peter M. Fasolo (Option Excercise at a value of $0), Robert J. Decker (Option Excercise at a value of $0), Thibaut Mongon (Option Excercise at a value of $1 738 618), Thibaut Mongon (Sold 39 224 shares of value $5 803 583 ), William D. Perez (Buy at a value of $63 843)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
11 (68.75 %)
11 (73.33 %)
9 (64.29 %)
Moderate Buy
1 (6.25 %)
1 (6.67 %)
1 (7.14 %)
Hold
4 (25.00 %)
3 (20.00 %)
4 (28.57 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.56
Strong Buy
1.47
Moderate Buy
1.64

Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare company. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, close to half of total revenue is generated in the United States.

CEO: Alex Gorsky

Teplephone: +1 732 524-0400

Address: One Johnson & Johnson Plaza, New Brunswick 08933, NJ, USA

Number of employees: 135 100

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

54%46%

Bearish Bullish

49%51%

Bearish Bullish

51%49%

News

Stocktwits